Back to Search Start Over

Use of Spinal Cord Stimulators in Patients With Pacemakers or Implantable Cardiac Defibrillators: A Review of Documented Accounts of Interference

Authors :
Nicholas A. Zacharias
Joshua Manuel Martens
Kenneth Fiala
Christopher R. Glover
Alaa Abd-Elsayed
Source :
Neuromodulation: Technology at the Neural Interface. 26:43-56
Publication Year :
2023
Publisher :
Elsevier BV, 2023.

Abstract

Objectives To assess the currently available evidence regarding associations between spinal cord stimulator (SCS) lead type, clinical indications for device placement, and interference between SCSs and cardiac pacemakers (CPMs)/implantable cardioverter-defibrillators (ICDs). Study design Review of case reports and original research studies assessing the interference between SCS and CPM/ICD. Materials and methods PubMed and Cochrane databases were searched for articles commenting on the interference between SCS and CPM/ICD. The search criteria which generated the greatest number of relevant studies was (spinal cord stimulator AND [pacemaker OR implantable cardioverter defibrillator]). Additional, empiric review was conducted using JSTOR, ScienceDirect, and EBSCOhost databases; however, no additional eligible studies were identified. Data were extracted, summarized into tables, and quantitatively analyzed using LibreTexts and MedCalc software. Results There was no statistically significant interference observed between SCS and CPM/ICD devices in patients regardless of indication for SCS placement and SCS lead polarity. Limitations Limited by variability of patient cases and variability in maximum frequency and amplitude of SCS devices tried in individual cases. Also limited by small sample size and the absence of a standard definition for device interference across studies. Conclusions Interference between cardiac devices and SCSs is a rare occurrence. As there are currently no published guidelines, devices should be interrogated on a case-by-case basis in the SCS trial period (if implanted after cardiac device), during permanent implantation, and during scheduled follow-up visits. Peri-operative testing should include increasing the SCS settings to maximally tolerated levels with cardiac device set at its maximum sensitivity.

Details

ISSN :
10947159
Volume :
26
Database :
OpenAIRE
Journal :
Neuromodulation: Technology at the Neural Interface
Accession number :
edsair.doi.dedup.....624aab6f39f36850c5aaf031dc9c3d95